Welcome to our dedicated page for KYNTRA BIO SEC filings (Ticker: KYNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyntra Bio filings document the company's public-company governance, financial reporting, clinical-development updates, and Nasdaq listing matters. Recent 8-K reports cover results of operations and financial condition, including business updates tied to FG-3246, roxadustat, and the FG-3180 biomarker program.
The filing record also includes definitive proxy statements that disclose governance matters, executive compensation, equity awards, and shareholder voting information. Additional 8-K disclosure addresses Nasdaq continued-listing compliance, reflecting the company's capital-market and reporting obligations as a Nasdaq-listed biopharmaceutical issuer.
KYNTRA BIO, INC. director Ho Maykin received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036. They vest in four equal quarterly installments from the grant date, and this filing shows 7,000 options held directly after the award.
Kyntra Bio director Jeffrey L. Edwards received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and were granted as a compensation award rather than a market purchase or sale.
The award vests in four equal quarterly installments measured from the grant date and expires on June 11, 2036. Following this grant, Edwards holds options for 7,000 shares directly, giving him equity-based incentive aligned with the company’s future performance.
KYNTRA BIO, INC. director Michael Kauffman received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036. These options vest in four equal quarterly installments from the grant date, and his reported option holdings following this grant total 7,000 derivative securities.
KYNTRA BIO, INC. director James A. Schoeneck received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036.
The 7,000 options vest in four equal quarterly installments starting from the grant date. Following this award, Schoeneck holds 7,000 derivative securities directly in the form of these stock options.
Kyntra Bio, Inc. reported results from its 2026 annual stockholder meeting held on June 12, 2026. Stockholders elected Class III director Michael Kauffman, M.D., Ph.D., to serve until the 2029 annual meeting, with 1,239,169 votes for, no votes against, 51,081 withheld, and 1,444,428 broker non-votes.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 1,242,005 votes for, 23,606 against, 24,639 abstentions, and 1,444,428 broker non-votes. In addition, they ratified the Audit Committee’s selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 2,712,825 votes for, 14,392 against, and 7,461 abstentions.
KYNTRA BIO, INC. CEO Thane Wettig reported routine share updates in a Form 4. The filing shows 198 shares of common stock were disposed of to cover a tax obligation at $6.71 per share when restricted stock units vested, a non‑market transaction. After this withholding, he directly holds 27,005 common shares and has an additional 40 shares reported as indirectly owned through his spouse.
KYNTRA BIO, INC. Chief Financial Officer David DeLucia reported a routine tax-related share disposition tied to equity compensation. On the reported date, 52 shares of common stock were withheld by the company at a value of $6.71 per share to satisfy a tax obligation that arose when restricted stock units vested. Following this withholding, DeLucia holds 4,377 shares of KYNTRA BIO common stock directly.
Kyntra Bio, Inc. received $4.0 million from AstraZeneca Treasury Limited on June 2, 2026. This payment represents the second and final holdback under their February 20, 2025 share purchase agreement covering the sale of Kyntra’s China operations.
The China business was sold to AstraZeneca on August 29, 2025 for total consideration of approximately $220 million, including $85 million in enterprise value and about $135 million in net cash held in China. Kyntra had previously collected $210 million at closing and a first holdback of $6.0 million plus an additional $0.4 million after final net cash adjustments. With this latest $4.0 million payment, the company has now received all amounts owed under the agreement.
Kyntra Bio, Inc. received $4.0 million from AstraZeneca Treasury Limited on June 2, 2026. This payment represents the second and final holdback under their February 20, 2025 share purchase agreement covering the sale of Kyntra’s China operations.
The China business was sold to AstraZeneca on August 29, 2025 for total consideration of approximately $220 million, including $85 million in enterprise value and about $135 million in net cash held in China. Kyntra had previously collected $210 million at closing and a first holdback of $6.0 million plus an additional $0.4 million after final net cash adjustments. With this latest $4.0 million payment, the company has now received all amounts owed under the agreement.
KYNTRA BIO, INC. CEO and director Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings to 27,203 shares. A separate line shows 40 shares of common stock held indirectly through his spouse.
KYNTRA BIO, INC. CEO and director Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings to 27,203 shares. A separate line shows 40 shares of common stock held indirectly through his spouse.
KYNTRA BIO, INC. CEO Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, bringing his direct holdings to 27,203 shares. He also reports indirect ownership of 40 shares held by his spouse.
KYNTRA BIO, INC. CEO Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, bringing his direct holdings to 27,203 shares. He also reports indirect ownership of 40 shares held by his spouse.